[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to potential M. Verdict: Not uniquely determinable. The stem describes a patient with classic MELAS features (stroke-like episodes, mitochondrial myopathy, lactic acidosis) and 38% heteroplasmy for m.3243A>G in muscle. The question asks about the \\\"significance\\\" of this heteroplasmy level. Key issue: The stem already provides a \\\"compatible phenotype\\\" (recurrent stroke-like episodes, myopathy, lactic acidosis are pathognomonic for MELAS), making option C's qualifier \\\"supports diagnosis with compatible phenotype\\\" redundant—the phenotype is already described. Option C is keyed correct, stating 38% is \\\"above the threshold for clinical expression\\\" and \\\"supports diagnosis with compatible phenotype.\\\" However, the rationale contradicts itself: it states \\\">40% correlates with clinical manifestation\\\" yet claims \\\"30-40% with typical phenotype are diagnostic,\\\" placing 38% in an ambiguous zone. The stem lacks clarity on whether 38% alone is sufficient or borderline. Option A claims >60% is required (medically inaccurate for muscle). Medical accuracy: The heteroplasmy thresholds cited are imprecise; literature supports ~20-30% in muscle as pathogenic, not rigid 40% cutoffs. The item conflates threshold concepts. Minimal fix: Clarify whether the question tests threshold knowledge or clinical correlation, and correct the heteroplasmy threshold to align with current evidence (~20-30% in muscle).\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to potential M. Verdict: Not uniquely determinable. The stem describes a patient with classic MELAS features (stroke-like episodes, mitochondrial myopathy, lactic acidosis) and 38% heteroplasmy for m.3243A>G in muscle. The question asks about the \"significance\" of this heteroplasmy level. Key issue: The stem already provides a \"compatible phenotype\" (recurrent stroke-like episodes, myopathy, lactic acidosis are pathognomonic for MELAS), making option C's qualifier \"supports diagnosis with compatible phenotype\" redundant—the phenotype is already described. Option C is keyed correct, stating 38% is \"above the threshold for clinical expression\" and \"supports diagnosis with compatible phenotype.\" However, the rationale contradicts itself: it states \">40% correlates with clinical manifestation\" yet claims \"30-40% with typical phenotype are diagnostic,\" placing 38% in an ambiguous zone. The stem lacks clarity on whether 38% alone is sufficient or borderline. Option A claims >60% is required (medically inaccurate for muscle). Medical accuracy: The heteroplasmy thresholds cited are imprecise; literature supports ~20-30% in muscle as pathogenic, not rigid 40% cutoffs. The item conflates threshold concepts. Minimal fix: Clarify whether the question tests threshold knowledge or clinical correlation, and correct the heteroplasmy threshold to align with current evidence (~20-30% in muscle).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem presents a 19-year-old asymptomatic athlete with short QT syndrome (QTc 315ms), family history of sudden cardiac death, and gain-of-function KCNH2 mutation. The question asks for management per 2022 ESC guidelines. Key issue: The 2022 ESC guidelines for SQTS recommend ICD (Class IIa) for patients with pathogenic mutation AND family history of SCD, regardless of symptoms. Quinidine (Class IIb) is an alternative/adjunct but lower recommendation class. The stem provides both risk factors (pathogenic mutation + family SCD), making ICD (option B) defensible per guidelines. However, the keyed answer (C, quinidine) is also defensible as initial pharmacotherapy. The item is underspecified because it doesn't clarify whether the question seeks first-line therapy, whether ICD refusal occurred, or patient preference context. This creates multiple defensible answers (B and C). Medical accuracy: The explanation states ICD is 'reserved for symptomatic patients or aborted SCD,' which contradicts 2022 ESC guidelines that recommend ICD for asymptomatic patients with high-risk features (mutation + family history). Minimal fix: Specify 'initial pharmacological management' or 'if ICD is declined' to make quinidine uniquely correct, or update the key to B if asking for guideline-concordant management without qualifiers.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem presents a 19-year-old asymptomatic athlete with short QT syndrome (QTc 315ms), family history of sudden cardiac death, and gain-of-function KCNH2 mutation. The question asks for management per 2022 ESC guidelines. Key issue: The 2022 ESC guidelines for SQTS recommend ICD (Class IIa) for patients with pathogenic mutation AND family history of SCD, regardless of symptoms. Quinidine (Class IIb) is an alternative/adjunct but lower recommendation class. The stem provides both risk factors (pathogenic mutation + family SCD), making ICD (option B) defensible per guidelines. However, the keyed answer (C, quinidine) is also defensible as initial pharmacotherapy. The item is underspecified because it doesn't clarify whether the question seeks first-line therapy, whether ICD refusal occurred, or patient preference context. This creates multiple defensible answers (B and C). Medical accuracy: The explanation states ICD is 'reserved for symptomatic patients or aborted SCD,' which contradicts 2022 ESC guidelines that recommend ICD for asymptomatic patients with high-risk features (mutation + family history). Minimal fix: Specify 'initial pharmacological management' or 'if ICD is declined' to make quinidine uniquely correct, or update the key to B if asking for guideline-concordant management without qualifiers.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes thyroid storm with cardiogenic shock (LVEF 15%, CI 1.8) and pulmonary edema where beta-blockers cannot be used. Key discriminating findings: severe systolic dysfunction, low cardiac index, pulmonary edema, and beta-blocker intolerance. The clinical problem requires both inotropic support and afterload reduction without beta-adrenergic stimulation. However, multiple options are defensible: Milrinone (C) provides non-beta-adrenergic inotropy and vasodilation but risks hypotension in shock states. Levosimendan (D) offers calcium sensitization with vasodilation and has evidence in cardiogenic shock, though less familiar in US practice. Norepinephrine (A) is standard for cardiogenic shock with hypotension (implied by 'shock' terminology). The stem lacks critical hemodynamic details (actual blood pressure, SVR) needed to distinguish between vasopressor vs. inodilator priority. Medical accuracy issues: The rationale dismisses levosimendan based on 'limited data' despite European guidelines supporting its use in cardiogenic shock; milrinone's hypotensive effects in shock states are understated. The item conflates 'most appropriate initial therapy' without specifying whether BP support or contractility is the immediate priority. Minimal fix: Add explicit BP value (e.g., 'BP 85/50 mmHg') to clarify whether vasopressor or inodilator takes precedence, or specify 'normotensive cardiogenic shock' to justify pure inodilator choice.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes thyroid storm with cardiogenic shock (LVEF 15%, CI 1.8) and pulmonary edema where beta-blockers cannot be used. Key discriminating findings: severe systolic dysfunction, low cardiac index, pulmonary edema, and beta-blocker intolerance. The clinical problem requires both inotropic support and afterload reduction without beta-adrenergic stimulation. However, multiple options are defensible: Milrinone (C) provides non-beta-adrenergic inotropy and vasodilation but risks hypotension in shock states. Levosimendan (D) offers calcium sensitization with vasodilation and has evidence in cardiogenic shock, though less familiar in US practice. Norepinephrine (A) is standard for cardiogenic shock with hypotension (implied by 'shock' terminology). The stem lacks critical hemodynamic details (actual blood pressure, SVR) needed to distinguish between vasopressor vs. inodilator priority. Medical accuracy issues: The rationale dismisses levosimendan based on 'limited data' despite European guidelines supporting its use in cardiogenic shock; milrinone's hypotensive effects in shock states are understated. The item conflates 'most appropriate initial therapy' without specifying whether BP support or contractility is the immediate priority. Minimal fix: Add explicit BP value (e.g., 'BP 85/50 mmHg') to clarify whether vasopressor or inodilator takes precedence, or specify 'normotensive cardiogenic shock' to justify pure inodilator choice.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes deficiency of adenosine deaminase 2 (DADA2), a rare monogenic autoinflammatory disease characterized by recurrent strokes, livedo racemosa, and systemic vasculitis with confirmed biallelic ADA2 mutations and severely reduced enzyme activity. Key discriminating findings: (1) recurrent lacunar strokes in a child, (2) livedo racemosa, (3) systemic vasculitis, (4) ADA2 enzyme <5% normal, (5) confirmed biallelic loss-of-function mutations. The keyed answer (C: Etanercept) is the established first-line therapy for DADA2. TNF-α inhibition with etanercept has demonstrated efficacy in preventing stroke recurrence and controlling systemic manifestations in multiple case series and cohort studies. Alternative assessments: (A) Traditional immunosuppressants show limited efficacy in DADA2; (B) Rituximab lacks evidence as first-line therapy; (D) Anakinra (IL-1 blockade) is considered second-line when TNF inhibitors fail or are contraindicated; (E) Aspirin alone is insufficient for this inflammatory vasculopathy requiring immunomodulation. No logical issues: the stem provides sufficient detail for diagnosis, and etanercept is uniquely supported as first-line by current literature. Medical accuracy is high, consistent with expert consensus and published guidelines. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes deficiency of adenosine deaminase 2 (DADA2), a rare monogenic autoinflammatory disease characterized by recurrent strokes, livedo racemosa, and systemic vasculitis with confirmed biallelic ADA2 mutations and severely reduced enzyme activity. Key discriminating findings: (1) recurrent lacunar strokes in a child, (2) livedo racemosa, (3) systemic vasculitis, (4) ADA2 enzyme <5% normal, (5) confirmed biallelic loss-of-function mutations. The keyed answer (C: Etanercept) is the established first-line therapy for DADA2. TNF-α inhibition with etanercept has demonstrated efficacy in preventing stroke recurrence and controlling systemic manifestations in multiple case series and cohort studies. Alternative assessments: (A) Traditional immunosuppressants show limited efficacy in DADA2; (B) Rituximab lacks evidence as first-line therapy; (D) Anakinra (IL-1 blockade) is considered second-line when TNF inhibitors fail or are contraindicated; (E) Aspirin alone is insufficient for this inflammatory vasculopathy requiring immunomodulation. No logical issues: the stem provides sufficient detail for diagnosis, and etanercept is uniquely supported as first-line by current literature. Medical accuracy is high, consistent with expert consensus and published guidelines. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 32-week pregnant patient with fetal hydrops and mirror syndrome presenting with severe preeclampsia-like features, asking for the pathophysiologic mechanism. Key discriminating findings: fetal hydrops (fetal edema) and mirror syndrome (maternal edema mirroring fetal condition) with preeclampsia-like presentation. Mirror syndrome (Ballantyne syndrome) is characterized by the maternal-fetal-placental triad of edema. The keyed answer (B) correctly identifies placental edema releasing sFlt-1 as the mechanism linking mirror syndrome to preeclampsia-like features. This aligns with current understanding that placental dysfunction in mirror syndrome releases anti-angiogenic factors similar to preeclampsia pathophysiology. Alternative A (fetomaternal hemorrhage) causes anemia but not the preeclampsia phenotype. C (Rh antibodies) can cause fetal hydrops but doesn't explain maternal preeclampsia features. D (amniotic fluid embolism) is an acute catastrophic event, not mirror syndrome. E incorrectly dismisses the stated diagnosis. The item is medically accurate, reflecting established pathophysiology of mirror syndrome and its relationship to anti-angiogenic factor release. No logical flaws or missing critical details prevent unique answer selection. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 32-week pregnant patient with fetal hydrops and mirror syndrome presenting with severe preeclampsia-like features, asking for the pathophysiologic mechanism. Key discriminating findings: fetal hydrops (fetal edema) and mirror syndrome (maternal edema mirroring fetal condition) with preeclampsia-like presentation. Mirror syndrome (Ballantyne syndrome) is characterized by the maternal-fetal-placental triad of edema. The keyed answer (B) correctly identifies placental edema releasing sFlt-1 as the mechanism linking mirror syndrome to preeclampsia-like features. This aligns with current understanding that placental dysfunction in mirror syndrome releases anti-angiogenic factors similar to preeclampsia pathophysiology. Alternative A (fetomaternal hemorrhage) causes anemia but not the preeclampsia phenotype. C (Rh antibodies) can cause fetal hydrops but doesn't explain maternal preeclampsia features. D (amniotic fluid embolism) is an acute catastrophic event, not mirror syndrome. E incorrectly dismisses the stated diagnosis. The item is medically accurate, reflecting established pathophysiology of mirror syndrome and its relationship to anti-angiogenic factor release. No logical flaws or missing critical details prevent unique answer selection. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. The stem describes subendocardial late gadolinium enhancement (LGE) with epicardial sparing in EGPA cardiac involvement. Key discriminating finding: subendocardial LGE pattern. The critical issue is that subendocardial LGE is the classic pattern of ischemic injury from coronary artery disease, not the typical pattern of EGPA myocarditis. In EGPA and other inflammatory cardiomyopathies, LGE typically shows patchy mid-wall or epicardial distribution. Subendocardial LGE specifically suggests ischemic etiology requiring coronary evaluation. The keyed answer (C) incorrectly states this represents fibrotic EGPA with poor immunosuppression response, but the pattern described is atypical for EGPA myocarditis. The rationale's claim that 'epicardial LGE correlates with active myocarditis' is backwards – subendocardial is ischemic, epicardial/mid-wall is inflammatory. Option B (concomitant CAD requiring angiography) is the correct best answer given the subendocardial pattern. Medical accuracy issue: fundamental mischaracterization of LGE patterns in inflammatory vs ischemic disease. Minimal fix: Change stem to 'epicardial and mid-wall LGE with subendocardial sparing' to make C defensible, or rekey to B.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. The stem describes subendocardial late gadolinium enhancement (LGE) with epicardial sparing in EGPA cardiac involvement. Key discriminating finding: subendocardial LGE pattern. The critical issue is that subendocardial LGE is the classic pattern of ischemic injury from coronary artery disease, not the typical pattern of EGPA myocarditis. In EGPA and other inflammatory cardiomyopathies, LGE typically shows patchy mid-wall or epicardial distribution. Subendocardial LGE specifically suggests ischemic etiology requiring coronary evaluation. The keyed answer (C) incorrectly states this represents fibrotic EGPA with poor immunosuppression response, but the pattern described is atypical for EGPA myocarditis. The rationale's claim that 'epicardial LGE correlates with active myocarditis' is backwards – subendocardial is ischemic, epicardial/mid-wall is inflammatory. Option B (concomitant CAD requiring angiography) is the correct best answer given the subendocardial pattern. Medical accuracy issue: fundamental mischaracterization of LGE patterns in inflammatory vs ischemic disease. Minimal fix: Change stem to 'epicardial and mid-wall LGE with subendocardial sparing' to make C defensible, or rekey to B.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes an 11-month-old with a CNS tumor showing rhabdoid cells, SMARCB1 loss, and TYR-methylation class—diagnostic of atypical teratoid/rhabdoid tumor (ATRT). Key discriminating findings: (1) rhabdoid histology + SMARCB1 loss = ATRT hallmark; (2) TYR-methylation class specified. The question asks for the most critical prognostic factor in this subtype. Option D (DNA methylation subclassification) is correct: recent literature establishes that ATRT methylation classes (TYR, SHH, MYC) are the dominant prognostic stratifier, with TYR having ~90% 5-year survival versus MYC <30%. SMARCB1 loss (A) is universal/diagnostic but not prognostic. Age <3 years (B) is a traditional risk factor but secondary to molecular class. MYC amplification (C) is relevant but the question specifies TYR class, making methylation class itself the critical factor. Extent of resection (E) matters but is less dominant than molecular subtype. The item is logically valid: one best answer is defensible, the key matches, no contradictions exist, and options are discriminable. Medical accuracy is high, reflecting current ATRT risk stratification paradigms. Minimal fix: none needed; item is unambiguous and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes an 11-month-old with a CNS tumor showing rhabdoid cells, SMARCB1 loss, and TYR-methylation class—diagnostic of atypical teratoid/rhabdoid tumor (ATRT). Key discriminating findings: (1) rhabdoid histology + SMARCB1 loss = ATRT hallmark; (2) TYR-methylation class specified. The question asks for the most critical prognostic factor in this subtype. Option D (DNA methylation subclassification) is correct: recent literature establishes that ATRT methylation classes (TYR, SHH, MYC) are the dominant prognostic stratifier, with TYR having ~90% 5-year survival versus MYC <30%. SMARCB1 loss (A) is universal/diagnostic but not prognostic. Age <3 years (B) is a traditional risk factor but secondary to molecular class. MYC amplification (C) is relevant but the question specifies TYR class, making methylation class itself the critical factor. Extent of resection (E) matters but is less dominant than molecular subtype. The item is logically valid: one best answer is defensible, the key matches, no contradictions exist, and options are discriminable. Medical accuracy is high, reflecting current ATRT risk stratification paradigms. Minimal fix: none needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question asks which speckle-tracking finding best distinguishes ATTRwt from hypertensive heart disease in a patient with LV hypertrophy and reduced EF. Key discriminating finding: relative apical sparing ratio >1.5 (option B) is highly specific (93%) for cardiac amyloidosis due to base-to-apex gradient of amyloid deposition, not seen in hypertensive heart disease where strain reduction is uniform. Option A (GLS -8%) indicates severe dysfunction but is nonspecific. Option C (basal sparing) contradicts amyloidosis pathophysiology where basal segments are preferentially affected. Option D (circumferential strain >-15%) indicates dysfunction but lacks specificity. Option E describes basal predominance of strain reduction, opposite of the apical sparing pattern characteristic of amyloidosis. The keyed answer correctly identifies the pathognomonic finding that distinguishes these entities. Medical accuracy: The relative apical sparing pattern with ratio >1.5 is well-established in literature as highly specific for cardiac amyloidosis versus other causes of LVH. No logical issues; stem provides sufficient clinical context, and only one option represents the distinctive finding. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question asks which speckle-tracking finding best distinguishes ATTRwt from hypertensive heart disease in a patient with LV hypertrophy and reduced EF. Key discriminating finding: relative apical sparing ratio >1.5 (option B) is highly specific (93%) for cardiac amyloidosis due to base-to-apex gradient of amyloid deposition, not seen in hypertensive heart disease where strain reduction is uniform. Option A (GLS -8%) indicates severe dysfunction but is nonspecific. Option C (basal sparing) contradicts amyloidosis pathophysiology where basal segments are preferentially affected. Option D (circumferential strain >-15%) indicates dysfunction but lacks specificity. Option E describes basal predominance of strain reduction, opposite of the apical sparing pattern characteristic of amyloidosis. The keyed answer correctly identifies the pathognomonic finding that distinguishes these entities. Medical accuracy: The relative apical sparing pattern with ratio >1.5 is well-established in literature as highly specific for cardiac amyloidosis versus other causes of LVH. No logical issues; stem provides sufficient clinical context, and only one option represents the distinctive finding. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a calcium-channel blocker (verapamil) overdose with shock and hyperglycemia, for which high-dose insulin euglycemia therapy (HIET) is indicated. The question asks for the target glucose range during HIET. Key discriminating findings: severe CCB overdose, hypotension requiring HIET, baseline hyperglycemia. HIET uses insulin 0.5-1 unit/kg/hr for its inotropic/metabolic effects in CCB/beta-blocker toxicity. The keyed answer (B: 110-180 mg/dL) aligns with published toxicology literature and consensus recommendations for HIET, which advocate moderate glycemic control to balance insulin's therapeutic benefits against hypoglycemia risk. Option A (80-110) is too tight and increases hypoglycemia risk during high-dose insulin. Option C (180-250) is too permissive and may reduce insulin's metabolic efficacy. Option D (250-350) defeats the 'euglycemia' component of HIET. Option E is non-specific and inferior to evidence-based targets. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high; the 110-180 mg/dL target reflects standard toxicology practice for HIET. Minimal fix: None needed; item is clear and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a calcium-channel blocker (verapamil) overdose with shock and hyperglycemia, for which high-dose insulin euglycemia therapy (HIET) is indicated. The question asks for the target glucose range during HIET. Key discriminating findings: severe CCB overdose, hypotension requiring HIET, baseline hyperglycemia. HIET uses insulin 0.5-1 unit/kg/hr for its inotropic/metabolic effects in CCB/beta-blocker toxicity. The keyed answer (B: 110-180 mg/dL) aligns with published toxicology literature and consensus recommendations for HIET, which advocate moderate glycemic control to balance insulin's therapeutic benefits against hypoglycemia risk. Option A (80-110) is too tight and increases hypoglycemia risk during high-dose insulin. Option C (180-250) is too permissive and may reduce insulin's metabolic efficacy. Option D (250-350) defeats the 'euglycemia' component of HIET. Option E is non-specific and inferior to evidence-based targets. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high; the 110-180 mg/dL target reflects standard toxicology practice for HIET. Minimal fix: None needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question tests understanding of HHV-6 reactivation's prognostic significance in DRESS syndrome. Key stem clues: phenytoin-induced DRESS with classic features (fever, eosinophilia, atypical lymphocytosis, transaminitis), HHV-6 PCR positive at day 16 (week 2-3 timeframe). The keyed answer (C) correctly identifies that HHV-6 reactivation in DRESS is a prognostic marker associated with more severe disease, higher risk of flares, and end-organ damage. Option A is incorrect—HHV-6 reactivation doesn't confirm causative drug; clinical criteria do that. Option B is wrong—antivirals are not indicated for HHV-6 reactivation in DRESS as it reflects immune dysregulation, not primary infection requiring treatment. Option D contradicts established literature showing HHV-6 reactivation has clear prognostic value in DRESS. Option E is implausible—the temporal relationship (3 weeks post-drug) and clinical syndrome clearly indicate DRESS, not primary HHV-6 infection. Medical accuracy: The item accurately reflects current understanding that HHV-6 reactivation in DRESS (typically weeks 2-3) is a biomarker of disease severity and immune dysregulation, associated with worse outcomes. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question tests understanding of HHV-6 reactivation's prognostic significance in DRESS syndrome. Key stem clues: phenytoin-induced DRESS with classic features (fever, eosinophilia, atypical lymphocytosis, transaminitis), HHV-6 PCR positive at day 16 (week 2-3 timeframe). The keyed answer (C) correctly identifies that HHV-6 reactivation in DRESS is a prognostic marker associated with more severe disease, higher risk of flares, and end-organ damage. Option A is incorrect—HHV-6 reactivation doesn't confirm causative drug; clinical criteria do that. Option B is wrong—antivirals are not indicated for HHV-6 reactivation in DRESS as it reflects immune dysregulation, not primary infection requiring treatment. Option D contradicts established literature showing HHV-6 reactivation has clear prognostic value in DRESS. Option E is implausible—the temporal relationship (3 weeks post-drug) and clinical syndrome clearly indicate DRESS, not primary HHV-6 infection. Medical accuracy: The item accurately reflects current understanding that HHV-6 reactivation in DRESS (typically weeks 2-3) is a biomarker of disease severity and immune dysregulation, associated with worse outcomes. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]